Exendins, exendin agonists, and methods for their use

Details Exendins, exendin agonists, and methods for their use Exendins, exendin agonists, and methods for their use

2006-10-03

2006-10-03

Weber, Jon (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S300000, C530S324000, C424S185100

Reexamination Certificate

active

07115569

ABSTRACT:
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5574008 (1996-11-01), Johnson
patent: 5686511 (1997-11-01), Bobo
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 199731732 (1997-06-01), None
patent: WO 9011296 (1990-04-01), None
patent: WO 9111457 (1991-08-01), None
patent: WO 9318786 (1993-09-01), None
patent: WO 9325579 (1993-12-01), None
patent: WO 96/40196 (1996-12-01), None
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/19698 (1998-05-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
Adelhorst, K., et al, “Structure-activity studies of glucagon-like peptide-1 (GLP-1),”J. Bio Chem269(9):6275-8 (1994).
Bartlett, et al, “Inhibitionof Chymotrypsin by Phosphonate and Phosphonamidate Peptide Analogs,”Bioorg. Chem.14:356-377 (1986).
Bhavsar, “Inhibition of gastric emptying and of food intake appear to be independently controlled in rodents,”Soc. Neurosci. Abst.21:460 (188.8)(1995).
Cohen, et al,The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis,pp. 11-52, Millipore Corporation (1989).
D'Alessio et al. “Elimination of the Action of glucagon-like Peptide 1 Causes an Impairment of glucose tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest.,97:133-38, 1996.
Eissele et al. “Rat Gastric somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,”Life Sci.,55:629-34, 1994.
Eng et al. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom”,J. Biol. Chem.,267:7402-05, 1992.
Eng et al. “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem.,265:20259-62, 1990.
Fehmann et al. “Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),”Peptides15 (3): 453-6, 1994.
Ferguson et al. “Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures”,Annu. Rev. Biochem.57:285-320 (1988).
Goke et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting -Cells”,J. Biol. Chem.,268:19650-55, 1993.
Halaas, J.L., et al, “Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene,”Science269:543-546 (1995).
Kodama, J., et al, “Effect of Captopril on Glucose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow,”Diabetes Care13(11):1109-1111 (1990).
Kolligs, et al, “Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonsit exendin (9-39) amide,”Diabetes44:16-19 (1995).
Leibel, R.L., et al, “Changes in Energy Expenditure Resulting from Altered Body Weight,”New England Journal of Medicine332(10):621-628 (1995).
Lithell, et al, “Insulin Sensitivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters,”J. Cardiovasc. Pharmacol.15 (Supp 5):S46-S52 (1990).
Malhotra et al. “Exendin-4, a new peptide fromHeloderma suspectumvenom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini”,Regulatory Peptides,41:149-56, 1992.
Montrose-Rafizadeh et al. “Structure-function Analysis of Exendin-4 / GLP-1 Analogs”,Diabetes,45(Suppl. 2):152A, 1996.
O'Halloran et al. “Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man,”J Endocrinol126 (1): 169-73 (1990).
Ørskov et al, “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable”,Diabetes,42:658-61 (1993).
Pelleymounter, et al, “Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice,”Science269:540-543 (1995).
Raufman et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini form Guinea Pig Pancrease”,J. Biol. Chem.267:21432-37 (1992).
Raufman et al. “Exendin-3, a Novel Peptide fromHeloderma horridumvenom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newy Described Receptor on dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem,266:2897-902 (1991).
Schepp et al. “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)Nh2,”Eur. J. Pharm,269:183-91 (1994).
Schjoldager et al. “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Dig Dis Sci34 (5): 703-8 (1989).
Singh et al. “Use of1251-[Y30]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,”Regul. Pept.53:47-59 (1994).
Thorens, “Expression cloning of the pancreatic cell receptor for the gluco-incretin hormone glucagon-like peptide 1, ”Proc. Natl. Acad. Sci. USA89:8641-45 (1992).
Thorens, et al. “Cloning and Functional Expression of the Human Islet GLP-1 Receptor,”Diabetes42 (11): 1678-82 (1993).
Turton, et al, “A role for glucagon-like peptide-1 in the central regulation of feeding,”Nature379:69-72 (1996).
Veale, P.R., et al, “The presence of islet amyloid polypeptide/calcitonin gen-related peptide/salmon calcitonin binding sites in the rat nucleus accumbens,”European Journal of Pharmacology262:133-141 (1994).
Wang et al. “Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,”J. Clin. Invest.,95:417-21 (1995).
Watson, N., et al, “Effects of captopril on glucose tolerance in elderly patients with congestive cardiac failure,”Current Medical Research and Opinion12(6):374-378 (1991).
Wettergren et al. “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Dig Dis Sci38 (4): 665-73 (1993).
Willms et al. “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Mel: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,”J. Clin. Endocrinol. Metab,81(1):327-32 (1996).
Young, et al,Program and Abstracts, 10thInternational Congress of EndocrinologyJun. 12-15, 1996, San Francisco, p. 419 (P2-58).
Tang-Christensen, M. et al., “Central Administration of GLP-1-(7-36) Amide Inhibits Food and Water Intake in Rats,” American Physiological Society 271 (4 Pt 2): R848-R856 (1996).
Lawler, R.L. et al., “Comparison of Effects of Amylin, Glucagon-like Peptide-1 (GLP-1) and Exendin-4 to Inhibit Pentagastrin-stimulated Gastric Acid Secretion in Rats,”Gastroenterology,XP-002167251, 112(4 Supp):A194 (1997).
Navarro, M. et al, “Colocalization of Glucagon

Affiliated with

Also associated with

Rating

Exendins, exendin agonists, and methods for their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Exendins, exendin agonists, and methods for their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendins, exendin agonists, and methods for their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3716128